Trial Information

Mild Cognitive Impairment

This study will investigate the potential treatment effects of IVIG (intravenous immunoglobulin) to target early Alzheimer's Disease in persons with MCI. MRI brain imaging and cognitive testing will be conducted over approximately 2 years.

Patient Inclusion Criteria:

50 - 84 years old
Male or Female
Memory complaints or any sign of memory dysfunction
Able to have MRI
Not currently taking cholinesterase-inhibitors (i.e., Aricept) or memantine (i.e.,Namenda)

Below are some of the exclusionary criteria that will exclude a subject from being enrolled into the study:

Has significant neurological disease, other than a-MCI that may affect cognition
History of clinically evident stroke or history of clinically significant carotid or vertebrobasilar stenosis or plaque.
presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, CSF shunts, metal fragments in body.
Clinically significant systemic illness present
Uncontrolled hypertension
History of cancer within past 5 years (except non metastatic basal cell carcinoma and squamous cell carcinoma of the skin).
Severe liver or kidney disease
others will be discussed at screening

Tammy Donnel, Clinical Research Coordinator
Sutter Institute for Medical Research (SIMR)
2801 Capitol Avenue Suite 210
Sacramento, CA 95816
Phone: 916-453-5994
Fax: 916-733-8968
Email: simr@sutterhealth.org

View Map

Research Center Information: Sutter Institute for Medical Research (SIMR)

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:
Message:

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.